title: Treatment of pneumonia in mechanically ventilated trauma patients. Results of a prospective trial.
abstract: OBJECTIVE
  To determine the efficacy and magnitude of associated adverse effects of 2 different antibiotic regimens for the treatment of pneumonia in intubated surgical patients and to assay and compare blood samples and bronchoalveolar lavage fluid with respect to some host-defense parameters, especially in patients with unilateral pneumonia.
  
  
  METHODS
  Randomized, prospective, unblinded clinical comparison of 2 treatment arms with respect to intent to treat and clinical and microbiologically evaluable patients.
  
  
  METHODS
  Six university surgical services in teaching hospitals with modern and well-staffed intensive care units.
  
  
  METHODS
  The consistency and objectively of the diagnosis of pneumonia was improved by the use of a grid of diagnostic parameters. Aggressive mechanical approaches to pneumonia in intubated surgical patients were supplemented by therapeutic use of aztreonam and vancomycin hydrochloride or combined imipenem and cilastatin sodium.
  
  
  RESULTS
  Patients randomized to the aztreonam-vancomycin group were somewhat more ill, fared slightly better, and had fewer serious drug-related side effects than did those treated with imipenem-cilastatin (all P > .05). Immunologic parameters assessed by evaluation of bronchoalveolar lavage fluid showed differences between infected pulmonary lobes and noninfected ones; some changes were also noted in patients who recovered compared with those whose pneumonia persisted or recurred.
  
  
  CONCLUSIONS
  Clinical studies of pneumonia in surgical patients need to be stratified to assure comparability, to identify patients in whom treatment is likely to fail, and to display differences between more and less effective therapies. Studies of blood and bronchoalveolar lavage samples showed that certain local and systemic immunologic parameters correlate with clinical status and outcome.
authors.affiliation: Department of Surgery, Price Institute of Surgical Research, University of Louisville School of Medicine, Ky, USA.
authors.forename: H C
authors.initials: HC
authors.lastname: Polk
authors.forename: D H
authors.initials: DH
authors.lastname: Livingston
authors.forename: D E
authors.initials: DE
authors.lastname: Fry
authors.forename: M A
authors.initials: MA
authors.lastname: Malangoni
authors.forename: T
authors.initials: T
authors.lastname: Fabian
authors.forename: L S
authors.initials: LS
authors.lastname: Trachtenberg
authors.forename: S A
authors.initials: SA
authors.lastname: Gardner
authors.forename: L
authors.initials: L
authors.lastname: Kesterson
authors.forename: W G
authors.initials: WG
authors.lastname: Cheadle
mesh_terms: D001398:Aztreonam / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D015377:Cilastatin / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D006684:HLA-DR Antigens / Q000096:biosynthesis; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D011014:Pneumonia / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D011446:Prospective Studies; D012121:Respiration, Artificial; D014640:Vancomycin / Q000627:therapeutic use*; D014947:Wounds and Injuries / Q000628:therapy
chemical_list: D006684:HLA-DR Antigens; D015377:Cilastatin; D014640:Vancomycin; D015378:Imipenem; D001398:Aztreonam